Evans formally abandons early stage biotech
Sir Christopher Evans has rebranded his firm Merlin Biosciences as Excalibur as he focuses more broadly across the medical sector with a number of planned funds.
4 January 2013•2 mins read
Sir Christopher Evans has rebranded his firm Merlin Biosciences as Excalibur as he focuses more broadly across the medical sector with a number of planned funds.
